المؤلفون: Gulikers, J L, van Veelen, A J, Driessen, J H M, Souverein, P C, Tjan-Heijnen, V C G, Hendriks, L E L, van Geel, R M J M, Croes, S

المساهمون: Afd Pharmacoepi & Clinical Pharmacology, Sub Gen. Pharmacoepi and Clinical Pharm, LS Nederlandse taalkunde, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology

مصطلحات موضوعية: CPRD Aurum, CPRD GOLD, database, primary care, Pharmacology (medical), Epidemiology

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/432842Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/432842Test

المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Peters , S , Planchard , D , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Oncogene-addicted metastatic non-small-cell lung cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 339-357 . https://doi.org/10.1016/j.annonc.2022.12.009Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.009Test
https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
https://cris.maastrichtuniversity.nl/ws/files/192165782Test/Hendriks-2023-Oncogene-addicted-metastatic-non-small.pdf

المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Planchard, D., Peters, S., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Planchard , D , Peters , S , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 358-376 . https://doi.org/10.1016/j.annonc.2022.12.013Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, immunotherapy, RANDOMIZED PHASE-III, QUALITY-OF-LIFE, PACLITAXEL DOUBLET CHEMOTHERAPY, RESPONSE EVALUATION CRITERIA, PLATINUM-BASED CHEMOTHERAPY, PEMETREXED PLUS CISPLATIN, SPECIFIED FINAL ANALYSIS, INDIVIDUAL PATIENT DATA, ELDERLY-PATIENTS, 2ND-LINE TREATMENT

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.013Test
https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test
https://cris.maastrichtuniversity.nl/ws/files/192165470Test/Hendriks-2023-Non-oncogene-addicted-metastatic-non.pdf

المؤلفون: Meertens, M, Muntinghe-Wagenaar, M B, Sikkema, B J, Lopez-Yurda, M, Retèl, V P, Paats, M S, Ter Heine, R, Schuuring, E, Timens, W, Touw, D J, van Boven, J F M, de Langen, A J, Hashemi, S M S, Hendriks, L E L, Croes, S, van den Heuvel, M M, Dingemans, Anne-Marie C, Mathijssen, R H J, Smit, E F, Huitema, A D R, Steeghs, N, van der Wekken, A J

المصدر: Meertens , M , Muntinghe-Wagenaar , M B , Sikkema , B J , Lopez-Yurda , M , Retèl , V P , Paats , M S , Ter Heine , R , Schuuring , E , Timens , W , Touw , D J , van Boven , J F M , de Langen , A J , Hashemi , S M S , Hendriks , L E L , Croes , S , van den Heuvel , M M , Dingemans , A-M C , Mathijssen , R H J , Smit , E F , Huitema ....

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/1269da41-d5cc-4761-8e6b-8a60aa2ecedbTest

الإتاحة: https://doi.org/10.3389/fonc.2023.1136221Test
https://hdl.handle.net/11370/1269da41-d5cc-4761-8e6b-8a60aa2ecedbTest
https://research.rug.nl/en/publications/1269da41-d5cc-4761-8e6b-8a60aa2ecedbTest
https://pure.rug.nl/ws/files/622662944/fonc_13_1136221.pdfTest

المؤلفون: Gulikers, J. L., van Veelen, A. J., Driessen, J. H. M., Souverein, P. C., Tjan‐Heijnen, V. C. G., Hendriks, L. E. L., van Geel, R. M. J. M., Croes, S.

المصدر: Pharmacoepidemiology and Drug Safety ; volume 32, issue 10, page 1161-1177 ; ISSN 1053-8569 1099-1557

الإتاحة: https://doi.org/10.1002/pds.5637Test

المؤلفون: Parikh K., Hendriks L. E. L., Bironzo P., Remon J.

المساهمون: Parikh K., Hendriks L.E.L., Bironzo P., Remon J.

مصطلحات موضوعية: Immune checkpoint inhibitor, Ipilimumab, Mesothelioma, Nivolumab, Pembrolizumab, Antineoplastic Combined Chemotherapy Protocol, Clinical Trials, Phase I as Topic, Phase II as Topic, Phase III as Topic, Human, Pleural Neoplasm, Randomized Controlled Trials as Topic, Salvage Therapy

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34174669; info:eu-repo/semantics/altIdentifier/wos/WOS:000693067900005; volume:99; firstpage:102250; lastpage:102257; numberofpages:8; journal:CANCER TREATMENT REVIEWS; http://hdl.handle.net/2318/1839581Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85108429543

الإتاحة: https://doi.org/10.1016/j.ctrv.2021.102250Test
http://hdl.handle.net/2318/1839581Test

المؤلفون: Remon J., Hendriks L. E. L., Bironzo P.

المساهمون: Remon J., Hendriks L.E.L., Bironzo P.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34883215; info:eu-repo/semantics/altIdentifier/wos/WOS:000746376800002; volume:33; issue:2; firstpage:123; lastpage:125; numberofpages:3; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2318/1839401Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85121217147

الإتاحة: https://doi.org/10.1016/j.annonc.2021.11.019Test
http://hdl.handle.net/2318/1839401Test

المؤلفون: Dingemans, A. M.C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., De Ruysscher, D., Van Schil, P. E., Vansteenkiste, J., Reck, M.

المصدر: ESMO Guidelines Committee , Dingemans , A M C , Früh , M , Ardizzoni , A , Besse , B , Faivre-Finn , C , Hendriks , L E , Lantuejoul , S , Peters , S , Reguart , N , Rudin , C M , De Ruysscher , D , Van Schil , P E , Vansteenkiste , J & Reck , M 2021 , ' Small-cell lung cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ☆ ' , Annals of oncology : official journal of the European Society for Medical Oncology , ....

مصطلحات موضوعية: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being

العلاقة: https://pure.eur.nl/en/publications/cef306ae-23e7-437a-b3fa-d0f241c6177fTest

الإتاحة: https://doi.org/10.1016/j.annonc.2021.03.207Test
https://pure.eur.nl/en/publications/cef306ae-23e7-437a-b3fa-d0f241c6177fTest
http://www.scopus.com/inward/record.url?scp=85107245546&partnerID=8YFLogxKTest

المؤلفون: Noordhof, A L, Damhuis, R A M, Hendriks, L E L, de Langen, A J, Timens, W, Venmans, B J W, van Geffen, W H

المصدر: Noordhof , A L , Damhuis , R A M , Hendriks , L E L , de Langen , A J , Timens , W , Venmans , B J W & van Geffen , W H 2021 , ' Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy ' , Lung Cancer , vol. 155 , pp. 163-169 . https://doi.org/10.1016/j.lungcan.2021.04.001Test

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/d74de2bb-2b11-4f42-a7e3-aaa2ded9c096Test

الإتاحة: https://doi.org/10.1016/j.lungcan.2021.04.001Test
https://hdl.handle.net/11370/d74de2bb-2b11-4f42-a7e3-aaa2ded9c096Test
https://research.rug.nl/en/publications/d74de2bb-2b11-4f42-a7e3-aaa2ded9c096Test
https://pure.rug.nl/ws/files/168905785/Prognostic_impact_of_KRAS_mutation_status_for_patients_with_stage_IV_adenocarcinoma_of_the_lung_treated_with_first_line_pembrolizumab_monotherapy.pdfTest

المؤلفون: Cortiula F., De Ruysscher D., Steens M., Wijsman R., van der Wekken A., Alberti M., Hendriks L. E. L.

المساهمون: Cortiula, F., De Ruysscher, D., Steens, M., Wijsman, R., van der Wekken, A., Alberti, M., Hendriks, L. E. L.

مصطلحات موضوعية: Adjuvant immunotherapy, Driver genomic alteration, KRAS mutation, Progression-free survival, Stage III NSCLC, Uncommon driver genomic alteration, Unresectable NSCLC

العلاقة: volume:184; firstpage:172; lastpage:178; numberofpages:7; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11390/1244794Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85150039408

الإتاحة: https://doi.org/10.1016/j.ejca.2023.02.013Test
https://hdl.handle.net/11390/1244794Test